PORTFOLIO

Our vision is to make expert ultrasound available to every physician and every patient globally. Our initial focus is to help millions of women who suffer for years from pain and infertility due to endometriosis without a diagnosis.
10% of the female population in childbearing age is suffering from endometriosis. Patients with endometriosis face a delay in diagnosis of 8-12 years. This delay significantly impacts their quality of life due to severe pain and reduced fertility and poses a considerable economic burden on society.
Scanvio is developing intelligent algorithms to replace the previous gold standard invasive laparoscopy with non-invasive AI-supported ultrasound for faster and more accessible diagnosis of endometriosis. We specialize in AI-assisted medical ultrasound solutions provided as Software-As-Medical-Device (SAMD). Trained on expert data, our innovative software acts as an informative overlay during ultrasound examinations, reducing operator dependency and enabling any gynecologist to perform expert-level scans.
Scanvio is a great example whereby AI allows the integration of expert skills and procedural knowledge into applications and enables less skilled users to achieve the quality level of highly trained experts, thereby democratizing expertise and providing reliable, accessible, and equitable.

The project successfully translated an AI-based ultrasound innovation into real clinical use. With the development of the Scanvio Box™, Scanvio enabled real-time AI support on standard ultrasound systems and demonstrated first-in-patient use at Kantonsspital Baden.
Building on this milestone, the solution was rapidly adopted across multiple clinical sites, including Fontana Kantonsspital Chur, Privatklinik Bethanien, University Hospital Zurich. These real-world deployments confirmed the feasibility of AI-guided ultrasound in routine practice and highlighted strong demand from clinicians.
The project significantly accelerated Scanvio’s transition from research to implementation. It reduced technical and clinical risk, enabled follow-up seed financing, and laid the foundation for broader validation, regulatory progress and market entry. The results are being translated into clinical practice through Scanvio Medical AG.